THERAPY DOSSIER · th-d8f929d23b24

Allogeneic bone-marrow-derived endothelial progenitor cells (EPCs)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00629096 ↗PHASE2completed

Intracoronary Infusion of Bone Marrow-derived Progenitor Cells in Non-ischemic Dilated Cardiomyopathy

Dilated Cardiomyopathy

Enrolment: 27 · Results not recorded

NCT01333228 ↗PHASE1/PHASE2completed

Pilot Phase I/II Trial of Autologous Bone Marrow-derived EPCs in Advanced Liver Cirrhosis

Liver Cirrhosis

Enrolment: 14 · Results not recorded

NCT03103295 ↗PHASE1/PHASE2unknown

Traumatic Bone Defects Treatment With 3D Tissue Engineered Equivalent

Bone Defects

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28335684 ↗2017Mixed findings

Bone-Marrow-Derived Endothelial Progenitor Cell Treatment in a Model of Lateral Fluid Percussion Injury in Rats: Evaluation of Acute and Subacute Outcome Measures.

RatTBIFluid percussionSprague-DawleyMale

Model: Lateral fluid percussion injury

EPC treatment reduced activated caspase-3 and PARP cleavage at 72 h post-injury and significantly improved rotarod locomotor performance, but had non-significant effects on microvascular outcome, hippocampal neuronal density and spatial memory at 30 days.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…